Technical Analysis for ALNY - Alnylam Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
B 205.24 0.66% 1.34
ALNY closed down 2.23 percent on Monday, October 18, 2021, on 61 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Nov 3
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical ALNY trend table...

Date Alert Name Type % Chg
Overbought Stochastic Strength 0.66%
Narrow Range Bar Range Contraction -1.59%
NR7 Range Contraction -1.59%
Inside Day Range Contraction -1.59%
Overbought Stochastic Strength -1.59%
New 52 Week Closing High Bullish -1.94%
Pocket Pivot Bullish Swing Setup -1.94%
New 52 Week High Strength -1.94%
Overbought Stochastic Strength -1.94%
Cup with Handle Other 0.66%
Older End-of-Day Signals for ALNY ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1% about 3 hours ago
60 Minute Opening Range Breakout about 3 hours ago
Rose Above 10 DMA about 4 hours ago
Fell Below Previous Day's Low about 4 hours ago
Down 1% about 4 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Alnylam Pharmaceuticals, Inc. Description

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-AS1 for the treatment of acute intermittent porphyria; ALN-PCS for the treatment of hypercholesterolemia; and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia. The company's early stage program comprise ALN-AAT, an RNAi therapeutic targeting the mutant Z-allele in alpha-1-antitrypsin deficiency (AAT deficiency) for the treatment of AAT deficiency-associated liver disease. It also has two partner-based programs in clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus infection; and ALN-VSP for the treatment of liver cancers, as well as one candidate in pre-clinical development comprising ALN-HTT for the treatment of Huntington's disease. The company has strategic alliances with F. Hoffmann-La Roche Ltd; Arrowhead Research Corporation; Takeda Pharmaceutical Company Limited; Monsanto Company; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Genzyme Corporation; The Medicines Company; Cubist Pharmaceuticals, Inc; Biogen Idec Inc.; and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Clinical Development Cholesterol Hemoglobin Amyloid Liver Disease Takeda Pharmaceutical Company Hemophilia Amyloidosis Huntington's Disease Antitrypsin Deficiency Hemophilia A Spinal Muscular Atrophy Hypercholesterolemia Rna Interference Alnylam Pharmaceuticals Genzyme Liver Cancer Thalassemia Transthyretin Treatment Of Hemophilia Deficiency Hemoglobinopathies Therapeutic Gene Modulation Acute Intermittent Porphyria Beta Thalassemia Liver Cancers Medtronic Monsanto

Is ALNY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 211.97
52 Week Low 119.29
Average Volume 517,753
200-Day Moving Average 164.20
50-Day Moving Average 195.88
20-Day Moving Average 195.26
10-Day Moving Average 203.97
Average True Range 6.15
ADX 27.72
+DI 26.25
-DI 16.76
Chandelier Exit (Long, 3 ATRs) 193.54
Chandelier Exit (Short, 3 ATRs) 192.83
Upper Bollinger Bands 215.12
Lower Bollinger Band 175.41
Percent B (%b) 0.72
BandWidth 20.34
MACD Line 4.44
MACD Signal Line 3.05
MACD Histogram 1.3826
Fundamentals Value
Market Cap 23.69 Billion
Num Shares 116 Million
EPS -8.25
Price-to-Earnings (P/E) Ratio -24.70
Price-to-Sales 37.25
Price-to-Book 12.54
PEG Ratio -0.49
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 213.74
Resistance 3 (R3) 214.30 211.58 212.10
Resistance 2 (R2) 211.58 209.07 211.30 211.55
Resistance 1 (R1) 207.74 207.53 206.38 207.18 211.01
Pivot Point 205.02 205.02 204.34 204.74 205.02
Support 1 (S1) 201.18 202.51 199.82 200.62 196.79
Support 2 (S2) 198.46 200.97 198.18 196.25
Support 3 (S3) 194.62 198.46 195.70
Support 4 (S4) 194.06